Mindset Pharma Announces Closing of Arrangement
Mindset Pharma Announces Receipt of Final Order
Mindset Pharma Announces Shareholder Approval of Arrangement
Mindset Pharma Provides Clarifying Disclosure in Connection with Proposed Plan of Arrangement
Mindset Pharma Announces Mailing of Circular and Receipt of Interim Order
Mindset Pharma to be acquired by Otsuka Pharmaceutical in all-cash deal
Otsuka Pharmaceutical to Acquire Mindset Pharma
Mindset Pharma's Phase 2 psilocin prodrug study gets green light from UK regulators
Mindset Pharma files two international patent applications under the Patent Cooperation Treaty
Mindset Pharma CEO discusses expansion of drug discovery efforts into novel non-hallucinogenic therapeutics
Mindset Pharma and PharmAla complete first sale of pharmaceutical-grade psilocybin into growing Australian market via sales partnership
Mindset Pharma receives another allowance for US patent application expanding composition of matter for Family 1 psilocybin analogs
Mindset Pharma receives allowance for US patent application covering lead psychedelic therapeutic candidate
Mindset Pharma to Participate in Upcoming Conferences in December 2022
Mindset Pharma spotlights recent achievements ahead of ‘even more exciting 2023' in shareholder update
Mindset Pharma and PharmAla Biotech forge exclusive sales agreement
Mindset Pharma presents data showing its psilocin prodrug is better tolerated than psilocybin
Mindset Pharma chooses pair of psychedelic drug candidates to move Family 2 program forward
Mindset Pharma provides strategic intellectual property license to Cybin for preclinical psychedelic drug research
Mindset Pharma to advance lead psychedelic drug candidate MSP-1014 into Phase 1 first-in-human trial
Mindset Pharma files 16 national patent applications to protect family of novel next-generation psychedelics
Mindset Pharma expands IP portfolio with three non-tryptamine families of next-gen psychedelic compounds
Mindset Pharma CEO spotlights firm's intranasal formulation technology, robust IP portfolio and partnerships
Mindset Pharma granted allowance for patent covering its short-duration novel psychedelic medications
Mindset Pharma develops new patent-pending technology to deliver next generation psychedelic medicines intranasally
Mindset Pharma partners with the Center for Addiction and Mental Health for study comparing its novel compound MSP-1014 with psilocybin
Mindset Pharma receives Notice of Allowance for psilocin derivatives patent application for treating central nervous system disorders
Mindset Pharma to Participate in Upcoming Conferences in June 2022
Mindset Pharma progresses plans for clinical trials of its advanced pre-clinical psychedelic MSP-1014
Mindset Pharma to Participate in Upcoming Conferences in May 2022
Mindset Pharma strengthens IP portfolio with new provisional patent application
Mindset Pharma to Participate in Upcoming Conferences in April 2022
Mindset Pharma CEO James Lanthier says company pursuing development partners to support clinical process
Mindset Pharma identifies new pharmacological insights of first-generation psychedelics through its COPE program with InterVivo Solutions
Mindset Pharma appoints Dr Fiona Randall as senior vice president of external alliance and scientific strategy
Mindset Pharma identifies additional drug candidates from 'Family 3' compounds
Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today
Mindset Pharma enters manufacturing deal with leading CDMO for next-generation psilocybin drug candidate, MSP-1014
Mindset Pharma Teams Up With The McQuade Center To Develop 2 Families Of Novel Psychedelic Compounds
Stifel GMP encouraged by US$5M investment into Mindset Pharma, which provides "further validation for psychedelic sector"
Mindset Pharma partners with McQuade Center for Strategic Research and Development to develop psychedelic medicine
Mindset Pharma recaps 2021 milestones as it expands portfolio of next-generation psychedelic compounds
Mindset Pharma leading the charge to advance psychedelic medicines to treat mental illness
Mindset Pharma files international patent application covering its Family 3 psychedelic compounds
Mindset to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
Mindset Pharma is pursuing breakthroughs in the psychedelics field with the help of “hard science”
Mindset Pharma announces poster presentation on lead candidate at Society for Neuroscience meeting
HC Wainright & Co starts coverage on Mindset Pharma with a Buy rating and C$5 price target
HC Wainright & Co starts covering Mindset Pharma with a Buy rating and C$5 price target
HC Wainright & Co starts coverage of Mindset Pharma with a Buy rating and C$5 price target